Ahmedabad-based Zydus Cadila acquired six brands from the Indian unit of Merck for an undisclosed amount.
The acquired products are anabolic steroid- Durabolin, Deca-Durabolin; injectable testosterone blend- Sustanon; Sicastat used for the treatment of oozing of blood; Multiload– intrauterine contraceptives and Axeten range which are angiotensin II antagonists used for the hypertension management.
“We have a longstanding association with MSD in India. The brands with their strong equity are a perfect addition and complement our core business and brands. We look at this as a great opportunity to strengthen our core offerings to create value and growth,” said Sharvil Patel, chairman of Zydus Healthcare.
The whole acquired portfolio fetched about INR 84 crore in 2015 sales. According to a statement, Merck has transferred the distribution and commercialization rights and assigned trademarks of the six brands to Zydus for the Indian market. Zydus has also gained the distribution and commercialization rights for Deca-Durabolin and Durabolin for Nepal.
Last month, Cadila Healthcare transferred its India human formulations business to Zydus Healthcare on a slump sale basis for INR 69.3 crore.
Featured Image Credit: Bigstockphoto